Ensuring the safety of HIV/AIDS generics [3]

Lancet

Volumn 365, Issue 9475, 2005, Pages 1926-

  Adelman, Carol C ^a  

^a HUDSON INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; STAVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE POLICY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFORMED CONSENT; LETTER; PRIORITY JOURNAL; SIDE EFFECT; STANDARDIZATION; WORLD HEALTH ORGANIZATION;

EID: 20444363817     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)66655-X     Document Type: Letter

References (4)

1. KR Frost Ensuring the safety of HIV/AIDS generics Lancet 365 2005 1290 91
2. C Adelman, J Norris Generic medicines are not substandard medicines Lancet 359 2002 1351 52
3. Food and Drug Administration FDA grants tentative approval to generic AIDS drug regimen for potential purchase under the President's Emergency Plan for AIDS Relief http://www.fda.gov/bbs/topics/news/2005/NEW01152.html (accessed May 9, 2005)
4. C Adelman, J Norris, J Weicher Myths and realities on prices of AIDS drugs 2004 Hudson Institute Washington, DC